Deutsche Bank’s NewAmsterdam Pharma NAMS Stock Holding History

Deutsche Bank’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.97M	Buy	204,457 +4,526	+2%	+$125K	﹤0.01%	1243
2026 Q2	$6.78M	Buy	199,931 +75,156	+60%	+$2.48M	﹤0.01%	1215
2026 Q1	$3.99M	Buy	124,775 +812	+0.7%	+$26.4K	﹤0.01%	1418
2025 Q4	$4.35M	Buy	123,963 +55,538	+81%	+$2.02M	﹤0.01%	1366
2025 Q3	$1.95M	Buy	68,425 +333	+0.5%	+$7.98K	﹤0.01%	1783
2025 Q2	$1.23M	Sell	68,092 -4,305	-6%	-$78.5K	﹤0.01%	1965
2025 Q1	$1.48M	Buy	72,397 +69,749	+2,634%	+$1.55M	﹤0.01%	1945
2024 Q4	$68.1K	Buy	2,648 +199	+8%	+$4.23K	﹤0.01%	3371
2024 Q3	$40.7K	Buy	+2,449	New	+$42.4K	﹤0.01%	3398

Other funds holding NAMS

Medicxi Ventures Management St. Helier, Jersey $127M AUM 21.77% 1-Year Est. Return

TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Mizuho Markets Cayman Grand Cayman, Cayman Islands $2.12B AUM 114.77% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Peregrine Capital Management Minneapolis, Minnesota $2.95B AUM 28.43% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Kornitzer Capital Management Shawnee Mission, Kansas $4.8B AUM 30.14% 1-Year Est. Return

DCF Advisers Greenwich, Connecticut $444M AUM 151.5% 1-Year Est. Return

Deutsche Bank's NAMS Position: Q3 2026 in Review

Deutsche Bank increased its NewAmsterdam Pharma (NAMS) stake by 2.3% in Q3 2026, buying an estimated $125K and bringing the position to 204,457 shares worth $4.97M. The position accounts for ﹤0.01% of the portfolio, ranked #1243.

Deutsche Bank first reported a position in NAMS in Q3 2024 and has held it in 9 quarters since. The position peaked at $6.78M in Q2 2026. 58 funds tracked by Wall St. Rank hold NAMS as of Q3 2026.

Deutsche Bank held 204,457 shares of NewAmsterdam Pharma worth $4.97M as of Q3 2026.
Deutsche Bank bought 4,526 NewAmsterdam Pharma shares in Q3 2026, an estimated $125K.
NewAmsterdam Pharma made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #1243 holding.
Deutsche Bank first reported a position in NewAmsterdam Pharma in Q3 2024 and has held it in 9 quarters since.
Deutsche Bank's NewAmsterdam Pharma position peaked at $6.78M in Q2 2026.
58 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.